That's an excellent one. New to me in 2013, but I see Biomaven posted in 2011. It's one of the main sources for my next indication summary of Pona: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85764510 But note Timmy C, Willy S., and others are part of the et al. The upcoming AACR presentation appears to be 3rd-party, albeit a Pona collaborator. Do you think Dr. Druker dusts off the diagnostic in light of EMA approval for 1st line T315i?